中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (4): 713-714.doi: 10.4103/1673-5374.353492

• 观点:视神经损伤修复保护与再生 • 上一篇    下一篇

DPP-IV抑制剂的眼部局部给药:治疗糖尿病诱导的视网膜神经变性的新方法

  

  • 出版日期:2024-04-15 发布日期:2023-09-15

Topical ocular administration of DPP-IV inhibitors: a new approach for treating diabetes-induced retinal neurodegeneration

Rafael Simó*, Cristina Hernández   

  1. Diabetes and Metabolism Research Unit, Vall d’Hebron Research Institute (VHIR); Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain
  • Online:2024-04-15 Published:2023-09-15
  • Contact: Rafael Simó, MD, PhD, rafael.simo@vhir.org.
  • Supported by:
    This work was funded by grants from the Instituto de Salud Carlos III (DTS18/0163 and ICI20/00129) and co-funded by European Union.

摘要: https://orcid.org/0000-0003-0475-3096 (Rafael Simó)

Abstract: Retinal neurodegeneration plays a significant role in the pathogenesis of diabetic retinopathy (DR), the leading cause of preventable blindness. In fact, the American Diabetes Association has defined DR as a highly specific neurovascular complication (Solomon et al., 2017). Therefore, it is no longer acceptable to consider DR as merely a microvascular complication. In this regard, the term diabetic retinal disease (DRD) has been proposed as a broader term comprising microangiopathy and neurodegeneration. However, there are currently no treatments available that directly target the neurodegenerative changes of DR. This paper will give new insights into the translational research in this field with particular emphasis on glucagon-like peptide 1/dipeptidyl peptidase IV (GLP-1/DPP-IV) inhibitors.